Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03370965
Other study ID # 17/B/01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 7, 2019
Est. completion date June 2025

Study information

Verified date February 2022
Source University Hospital Center of Martinique
Contact Philippe CABRE, PhD
Phone 0596552261
Email philippe.cabre@chu-martinique.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Optic neuritis is a frequent cause of vision loss encountered by ophthalmologists in the Caribbean. The diagnosis is made on clinical grounds. Optic neuritis can occur either in an isolated manner or, most often, as the first symptom of multiple sclerosis (MS) or neuromyelitisoptica (NMO). These 2 demyelinating disorders differ by many means, including treatment and prognosis. MS can cause severe long-term disability while NMO is a short-term sight- and life-threatening condition causing potential relapses, which may require plasma exchanges. Furthermore, disease-modifying therapies used in NMO are different from those used in MS, which can worsen the natural history of NMO. Early differential diagnosis of these diseases is thus crucial for preventing severe visual loss and disability.


Description:

Background: Optic neuritis is a frequent cause of vision loss encountered by ophthalmologists in the Caribbean. The diagnosis is made on clinical grounds. Optic neuritis can occur either in an isolated manner or, most often, as the first symptom of multiple sclerosis (MS) or neuromyelitisoptica (NMO). These 2 demyelinating disorders differ by many means, including treatment and prognosis. MS can cause severe long-term disability while NMO is a short-term sight- and life-threatening condition causing potential relapses, which may require plasma exchanges. Furthermore, disease-modifying therapies used in NMO are different from those used in MS, which can worsen the natural history of NMO. Early differential diagnosis of these diseases is thus crucial for preventing severe visual loss and disability. Purpose: The investigators aim to identify early predictive factors (clinical, biological and radiological) of NMO occurrence in patients presenting with optic neuritis and with no prior history of demyelinating diseases. Method: The investigators will conduct a multicentric prospective study including all patients of 18 years or older, with no prior history of demyelinating disorders and presenting with a diagnosis of optic neuritis in Martinique, Guadeloupe, French Guiana, Saint-Martin and Saint-Barthélemy. Patients will first undergo a full neuro-ophthalmic examination which includes visual acuity, contrast vision, color vision, slit-lamp anterior segment and fundus examination as well as automatized visual field and optical coherence tomography of the optic nerves and retina. Patients will then be admitted to the Neurology and Ophthalmologic Department of the University Hospital of Martinique for optic neuritis emergency treatment, 3-Tesla brain and medullar MRIs, and ancillary testing. Specific NMO antibodies (AQP-4 and MOG) will be tested in all patients. Neuro-ophthalmic examination will be repeated after 3 days of IV steroids in order to decide on further treatment. Patients will be further monitored at 1, 6 and 12 months so as to determine the most likely etiology of optic neuritis with the aid of MS and NMO diagnosis criteria.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date June 2025
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patient aged 18 years or older at time of inclusion. 2. Table of unilateral or bilateral optic neuritis defined as follows (clinical diagnosis): 1. Visual sharpness (acuity and / or visual field) experienced acutely or subacutely (<1 month) unilateral or bilateral, not corrected by optical correction. 2. Absence of ophthalmologic lesion which may explain the visual loss. 3. Examination of the normal fundus or showing a pallor or papular edema. 4. Presence of relative pupillary deficit relative if unilateral attack. 3. Patient (s) affiliated to a social security scheme (beneficiary or beneficiary). 4. Patient who has given free and written consent. Exclusion Criteria: 1. Patients known to have an inflammatory disease of the central nervous system (MS, NMO, EMAD). 2. Known history of inflammatory pathology (lupus or sarcoidosis) or infectious pathology (syphilis, HIV) that may give rise to optical neuropathy. 3. Table suggestive of Leber's hereditary optic neuropathy (genetically confirmed). 4. Treatment in progress known to give optical neuropathies. 5. Consumption of toxic known to give optical neuropathies. 6. Drinking more than 3 alcohol drinks per day for men and 2 alcohol drinks per day for women over a period of more than 15 years. 7. Arguments for non-arteritic ischemic optic neuropathy defined by all of the following criteria: 1. Absence of pain in eye movements. 2. Altitudinal deficit of the visual field. 3. Choroidal ischemia with fluorescein angiography. 4. Presence of cardiovascular risk factors. 5. Absence of neurological signs related to inflammatory disease of the central nervous system. 8. Arguments for arterial ischemic optic neuropathy defined by all of the following criteria: 1. Absence of pain in eye movements. 2. Altitudinal deficit of the visual field. 3. Choroidal ischemia with fluorescein angiography. 4. Presence of symptoms suggestive of Horton's disease. 5. Absence of neurological signs related to inflammatory disease of the central nervous system. 9. Pregnant and lactating patients.

Study Design


Intervention

Diagnostic Test:
Neuro-ophtalmology examination
Patients will first undergo a full neuro-ophthalmic examination which includes visual acuity, contrast vision, color vision, slit-lamp anterior segment and fundus examination as well as automatized visual field and optical coherence tomography of the optic nerves and retina. Patients will then be admitted to the Neurology and Ophthalmologic Department for optic neuritis emergency treatment, 3-Tesla brain and medullar MRIs, and ancillary testing. Specific NMO antibodies (AQP-4 and MOG) will be tested in all patients. Neuro-ophthalmic examination will be repeated after 3 days of IV steroids in order to decide on further treatment.

Locations

Country Name City State
France CHU of Martinique Fort-de-France

Sponsors (3)

Lead Sponsor Collaborator
University Hospital Center of Martinique Hospital Center of Cayenne (French Guyana), University Hospital Center of Guadeloupe

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Final diagnosis using MS (McDonald, 2010) - Spatial dissemination One T2 lesion ore more in at least two of the four central nervous system territories considered to be characteristic of MS:
juxtacortical,
periventricular,
sub-tentorial,
medullary (in case of medullary syndrome or brain stem, symptomatic lesions are excluded from the diagnostic criteria and do not participate in the lesion count).
12 months
Primary Final diagnosis using MS (McDonald, 2010) - Time dissemination A new lesion in T2 and / or a lesion taking gadolinium on a follow-up MRI regardless of the time of initial MRI.
The simultaneous presence of asymptomatic lesions raised and not elevated by gadolinium at any time.
12 months
Primary NMO diagnosis criteria (Wingerchuk, 2015) - Diagnosis of NMO-SD with positive anti-AQP4 Antibody At least one main clinical criterion (1)
Exclusion of other diagnoses
12 months
Primary NMO diagnosis criteria (Wingerchuk, 2015) - Diagnosis of NMO-SD with anti-AQP4 negative antibody At least 2 main clinical criteria occurring in the context of one or more clinical outbreaks and meeting the following criteria
At least 1 of the 2 main clinical criteria should be optic neuritis, extensive longitudinal myelitis or area postrema syndrome.
Dissemination in space (at least 2 main criteria)
Respect of MRI imaging criteria (2)
Anti-AQP4 negative antibodies
Exclusion of differential diagnoses
12 months
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4